<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344641</url>
  </required_header>
  <id_info>
    <org_study_id>ISSEXEN0054</org_study_id>
    <nct_id>NCT02344641</nct_id>
  </id_info>
  <brief_title>Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients</brief_title>
  <official_title>Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy of heart function improvements in type 2 diabetes and heart&#xD;
      failure patients with exenatide, and also investigates the mechanisms of exenatide improving&#xD;
      heart function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study enrolls 234 patients with type 2 diabetes and heart failure. The patients have an&#xD;
      New York Heart Association (NYHA) functional class of II to IV, are randomly assigned to 2&#xD;
      groups. One group use exenatide , the other group is control group and each group has 117&#xD;
      patients. At the baseline, the 3rd day, the 28th day patients are required to complete the&#xD;
      heart failure examination: plasma N-terminal pro-B-type natriuretic peptide(NT-proBNP), 6-min&#xD;
      walking distance, echocardiographic measures, patient quality of life(MLHFQ). At the end of&#xD;
      4-week follow-up, we evaluate the efficacy of heart function improvements after treatment&#xD;
      with exenatide and also investigate the mechanisms of exenatide improving heart function .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in plasma NT-proBNP level after using exenatide for 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide group receive exenatide (5μg, subcutaneous injection, Bid）</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group do not receive exenatide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed Type 2 diabetes mellitus&#xD;
&#xD;
          2. HbA1c 7%-10% and Fasting plasma glucose(FBG) &lt;10mmol/L&#xD;
&#xD;
          3. Age 18-65 years&#xD;
&#xD;
          4. NT-proBNP level≥ 450 pg/ml&#xD;
&#xD;
          5. Left ventricular ejection fraction (LVEF)&lt;40%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncorrected primary vascular disease&#xD;
&#xD;
          2. congenital heart disease&#xD;
&#xD;
          3. Left ventricular outflow obstruction&#xD;
&#xD;
          4. Myocarditis&#xD;
&#xD;
          5. Aneurysm&#xD;
&#xD;
          6. uncontrolled severe arrhythmia&#xD;
&#xD;
          7. cardiogenic shock&#xD;
&#xD;
          8. unstable angina, or acute myocardial infarction&#xD;
&#xD;
          9. Severe primary hepatic, renal, or hematologic disease&#xD;
&#xD;
         10. Cr&gt;194.5 mmol/l or K+&gt;5.5 mmol/l&#xD;
&#xD;
         11. Systolic blood pressure (SBP) ≥180mm Hg or diastolic blood pressure (DBP) ≥110mm Hg&#xD;
&#xD;
         12. Alanine aminotransferase (ALT) &gt;3 times the upper normal limit&#xD;
&#xD;
         13. Patients were likely to undergo coronary artery bypass graft surgery during the&#xD;
             following 4 weeks&#xD;
&#xD;
         14. Patients had undergone or were likely to undergo cardiac resynchronization therapy&#xD;
&#xD;
         15. Pregnant or lactating known&#xD;
&#xD;
         16. Suspected to be allergic to the study drugs&#xD;
&#xD;
         17. Use dipeptidyl peptidase-4 (DPP-4) or glucagon-like peptide-1 (GLP-1) drug in 3 months&#xD;
&#xD;
         18. Hyperthyroidism and Hypothyroidism&#xD;
&#xD;
         19. Tumor&#xD;
&#xD;
         20. Received another investigational drug within 30 days prior to randomization&#xD;
&#xD;
         21. Severe mental health condition or other uncontrolled systemic disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YanYan Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fuwai Hospital, National Center for Cardiovascular Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>XinXing Feng, MD</last_name>
    <phone>:86-10-88396587</phone>
    <email>xinxing_feng@hotmail.com</email>
  </overall_contact>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>YanYan Chen</investigator_full_name>
    <investigator_title>Director，endocrinology and cardiology centre</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

